Retatrutide Peptide Powder 99% Purity CAS 2381089-83-2

Main Information on Ratrutide

Primary indication: Obesity treatment

Retatrutide has demonstrated significant weight-loss effects in multiple Phase II clinical trials:

The 12 mg dose group achieved an average weight loss of 24.2% (approximately 26 kg) over 48 weeks, with efficacy comparable to bariatric surgery (e.g., gastric sleeve resection). In both the 8 mg and 12 mg dose groups, over 85% of subjects exhibited complete resolution of hepatic steatosis (fat content <5%) at 48 weeks.

Type 2 Diabetes Management

Significantly reduced HbA1c (glycated hemoglobin) levels, with the maximum reduction reaching 2.02% (at doses of 4 mg and above, over 24 weeks). Improved insulin sensitivity and β -cell function, along with reduced insulin requirement.

Non-alcoholic fatty liver disease (NAFLD)/Non-alcoholic steatohepatitis (NASH)

In the NAFLD subgroup, the 8 mg and 12 mg dose groups demonstrated a relative reduction in liver fat>80% after 48 weeks, with 93% of patients achieving normalized liver fat levels (<5%). Improvement was observed in liver fibrosis markers (e.g., Pro-C3) and hepatocyte apoptosis markers (K-18).

Cardiovascular metabolic benefits

Improvement of lipid profile: TG reduced by 40%, LDL reduced by 22%. Reduction in both systolic and diastolic blood pressure. Phase III study currently underway for secondary prevention of cardiovascular events.

Other potential indications

Obstructive sleep apnea, obesity or overweight accompanied by chronic low back pain.

current state

Currently in Phase III clinical trials, it has not yet been commercialized. If subsequent data remain positive, it is expected to become a blockbuster drug for the next generation of metabolic disease treatments, with projected annual sales peaking at $27 billion.